Editas Medicine, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Cambridge, MA
EDIT chart
What traders are saying about $EDIT
Latest postsEditas Medicine, Inc. news
- Editas Medicine, Inc. Estimates – NASDAQ:EDIT
TradingView ·
- Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?
trefis.com ·
- Why Should You Think About Vertex Differently Now?
trefis.com ·
- Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Yahoo Finance ·
- Is Vertex Stock Worth More Than Its Competitors?
trefis.com ·
- EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Yahoo Finance ·
- Sector Update: Healthcare Stocks Softer Late Afternoon
Yahoo Finance ·
- Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
stocktwits.com ·
- Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Yahoo Finance ·
- CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
stocktwits.com ·
- CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
247wallst.com ·
- Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
marketbeat.com ·
Editas Medicine, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M |
| Net income | -$160.1M | -$237.1M | -$153.2M | -$220.4M |
| Diluted EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 |
| Total assets (year end) | $186.5M | $341.6M | $499.2M | $514.3M |
| Cash and equivalents (year end) | $146.6M | $131.5M | $123.7M | $141.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Editas Medicine, Inc.
- Ticker
- EDIT (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1650664
Frequently asked questions
What exchange is Editas Medicine, Inc. listed on?
Editas Medicine, Inc. trades on the Nasdaq under the ticker symbol EDIT.
What industry is Editas Medicine, Inc. in?
Editas Medicine, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Editas Medicine, Inc. headquartered?
Editas Medicine, Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Editas Medicine, Inc.'s fiscal year end?
Editas Medicine, Inc.'s fiscal year ends on December 31.
How much revenue did Editas Medicine, Inc. report?
Editas Medicine, Inc. reported $40.5M in revenue for calendar year 2025, according to its SEC filings.